Supplementary Materials and Methods and Supplementary Figures 1-5 from Therapeutic HPV Cancer Vaccine Targeted to CD40 Elicits Effective CD8+ T-cell Immunity
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Materials and Methods: This section includes additional Materials and Methods. Supplementary Figure S1: Specificity and binding ability of αCD40 (12E12) antibody. Supplementary Figure S2. αCD40-HPV16.E6/7 can target CD40 and can thus bind to human DCs and B cells. Supplementary Figure S3. αCD40-HPV16.E6/7 can induce E6/7-specific CD8+ and CD4+ T cell responses in vivo. Supplementary Figure S4. Poly(I:C) effectively enhances antigen-specific CD8+ T cell response in human in vitro. Supplementary Figure S5. Poly(I:C) effectively enhances antigen-specific CD8+ T cell response in CD40Tg mice in vivo.
Authors: Wenjie Yin, Dorothée Duluc, HyeMee Joo, Yaming Xue, Chao Gu, Zhiqing Wang, Lei Wang, Richard Ouedraogo, Lance Oxford, Amelia Clark, Falguni Parikh, Seunghee Kim-Schulze, LuAnn Thompson-Snipes, Sang-Yull Lee, Clay Beauregard, Jung-Hee Woo, Sandra Zurawski, Andrew G. Sikora, Gerard Zurawski, SangKon Oh
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362532447